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Background: Asthma is a chronic inflammatory airways disorder. However, no biomarker of
airways inflammation has been included in the assessment of asthma control.
Objective: To evaluate exhaled NO (FeNO) and exhaled breath condensate (EBC) pH in patients
with asthma according to the level of control, and their performance in the identification of
not well-controlled patients.
Methods: FeNO and EBC pH after Argon deaeration were measured in 274 consecutive patients.
Asthma control was evaluated by two asthma specialists blinded to FeNO and pH measure-
ments according to GINA guidelines, as well as by asthma control test (ACT) and asthma control
questionnaire (ACQ).
Results: FeNOwas higher and EBC pHwas lower in patients with notwell-controlled compared to
controlled asthma. In ROC analysis, FeNO presented an AUC of 0.790 for the identification of not
well-controlled asthma performing better in non-smokers; EBC pH presented an AUC of 0.791 for
the identification of notwell-controlled asthma, performing better in smokers. The performance
of both biomarkers was inferior to that of ACTand ACQ. FeNO values>30 ppb presented positive
predictive values (PPV) > 0.85 with the exception of smokers treated with inhaled corticoste-
roids. EBC pH values 7.20 presented PPV >0.80 in all groups. The presence of FeNO >30 ppb
and/or EBC pH 7.20 was indicative of not well-uncontrolled asthma in 88.3% of the patients.
Conclusion: FeNO and EBC pH levels may identify patients with not well-controlled asthma.
However, their performance was inferior to clinical judgment and may be limited to selected
subgroups of asthmatic patients.
ª 2010 Elsevier Ltd. All rights reserved.Karditsa 43100, Greece. Tel.: þ30 6944780616; fax: þ30 2441022370.
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Asthma is by definition a chronic inflammatory disorder of
the airways in which many cells and cellular elements play
a role.1 Current asthma guidelines have focused on asthma
control, both for the classification and for the proper
management of individual patients.1,2 The classification of
patients according to asthma control requires an evaluation
of symptoms, limitations in activities, use of rescue medi-
cation, history of exacerbations and pulmonary function
testing.1 In addition, the National Heart Lung and Blood
Institute have proposed the use of validated question-
naires,2 including the asthma control test (ACT)3 and the
asthma control questionnaire (ACQ).4 However, despite the
central role of inflammation in the pathogenesis and
natural history of asthma, no biomarker of airways inflam-
mation has been recommended in the assessment of control
in current asthma guidelines.
The relation between symptoms and airways inflamma-
tion remains a controversial issue, especially in complex
asthma.5 Symptom perception may be influenced by
several factors, including obesity6 and the coexistence of
anxiety and depression,7 and the inaccurate perception
of asthma symptoms is highly variable within persons.8
Therefore, there is a need for objective evaluation of
asthma symptoms and control, suggesting a possible role
for biomarkers of airway inflammation. This may further
facilitate management decisions, since the presence or
absence of inflammation may be used to guide treatment
modifications.9,10
The fraction of exhaled nitric oxide (FeNO) has been
widely evaluated as a marker of eosinophilic airways
inflammation, since it is readily measured, it provides
reproducible results, and is responsive to changes in
inhaled corticosteroid (ICS) doses.11 The ability of FeNO in
identifying well-controlled asthma has been evaluated in
children12 and in longitudinal studies in adults.13 However,
several confounding factors have been described in the
evaluation of FeNO, including smoking and treatment with
ICS.13,14
Exhaled breath condensate (EBC) pH has been found to
decrease in acute asthma and resolves with treatment,15
whereas stable patients with moderate asthma present
lower pH compared to mild disease.16 EBC pH is decreased
in smokers compared to non-smokers with allergic
rhinitis.17 Further, smoking patients with moderate to
severe asthma receiving ICS presented lower EBC pH values
compared to non-smokers,18 suggesting a possible role of
smoking in EBC pH regulation. Besides FeNO, EBC pH
represents the only exhaled biomarker to date that can be
measured on-site and that has been shown to be repro-
ducible and robust.19
The aim of this study was to evaluate the relation-
ships between two non-invasive, easy-to-perform on-site,
exhaled biomarkers (FeNO and EBC pH) in asthmatic
patients according to their level of control. Secondary aims
were to evaluate the diagnostic performance of FeNO and
EBC pH for the identification of not well-controlled (partly
controlled or uncontrolled) asthma in specific phenotypes
of asthmatic patients, according to treatment with inhaled
corticosteroids and their smoking habit.Methods
Study participants
Patients with a previously established diagnosis of asthma
that were evaluated in the outpatient asthma clinics of
two tertiary University hospitals between January 2007
and August 2008 were included in the study. Exclusion
criteria were: patients with a recent exacerbation (e.g.
requiring hospitalization or oral corticosteroids); patients
with another or coexisting respiratory disorder (e.g. COPD,
bronchiectasis); patients with recent smoking cessation (<2
months prior to the study) given that FeNO levels return to
normal levels 4e8 weeks after smoking cessation20 in order
to stratify our subjects as current smokers or non-smokers;
patients who had been previously included in this study.
The study protocol was approved by the Ethics
Committees of both hospitals and participants provided
written informed consent.
Study design details
Study participants sequentially undertook FeNO measure-
ment, EBC collection, spirometry with a dry spirometer
(KoKo Legend, Ferraris, UK) according to ATS recommen-
dations,21 and evaluation by respiratory physicians. FeNO
and EBC measurements were performed at 10:00e13:00
a.m. Subjects had not consumed food or beverages and had
not smoked for 2 h before.
Evaluation of asthma control
Asthma control was evaluated according to GINA guide-
lines1 by two respiratory physicians with special interest in
asthma (K.K. and S.L.) who were blinded to FeNO and EBC
pH measurements. Patients were classified as having “well-
controlled”, “partly controlled” or “uncontrolled” asthma,
according to GINA. Patients with partly controlled and
uncontrolled asthma were grouped as having “not well-
controlled” asthma. In addition, two validated question-
naires, the Asthma Control Test (ACT)3 and Juniper’s
Asthma Control Questionnaire (ACQ)4 were used.
Measurement of exhaled NO
FeNO was measured using a portable NO analyzer (NIOX
MINO Airway Inflammation Monitor, Aerocrine, Solna,
Sweden).22 MINO measurements were performed at an
expiratory flow rate of 50 mL/s, and are expressed as parts
per billion (ppb). Measurements with this portable analyzer
have previously been shown to be in clinically acceptable
agreement with measurements provided by a stationary
analyzer according to the ATS guidelines.23e25
Collection and measurement of exhaled breath
condensate pH
EBC was collected using a commercially available device
(EcoScreen, Viasys, Germany).17 Subjects rinsed their
mouth with distilled water and performed tidal breathing
528 K. Kostikas et al.for 15 min while wearing a nose clip. EBC pH was measured
using a commercially available pH meter (Model 3510,
Jenway, Essex, UK), immediately after the collection of
condensate.16 Stable pH was achieved after deaeration of
the EBC with argon (350 mL/min for 10 min).16
Statistical analysis
Normally distributed data are presented as mean  SD,
skewed data as median (interquartile ranges), and cate-
gorical data as n (%). Comparisons between groups were
performed with KruskalleWallis tests with Dunn’s post-hoc
tests. For the assessment of FeNO and EBC pH performance
as predictors of asthma control, receiver operating char-
acteristic (ROC) curves were created. Areas under the ROC
curves (AUC) with 95% confidence intervals (CI) and their
differences from 0.5 were calculated. Sensitivities, speci-
ficities, positive (PPV) and negative (NPV) predictive values
were calculated for the optimal cut-points. Statistical
analysis was performed with GraphPad Prism 5 (GraphPad
Software Inc, La Jolla, CA, USA) and MedCalc 9 (MedCalc
Software, Mariakerke, Belgium).
Results
Demographics and parameters related to asthma control in
the 274 patients whowere included are presented in Table 1.
Patients were additionally divided into four subgroups
according to their smoking status and their use of ICS: Group
1 e ICS-untreated non-smokers (n Z 48); Group 2 e ICS-
untreated smokers (n Z 32); Group 3 e ICS-treated non-
smokers (n Z 144); and Group 4 e ICS-treated smokers
(nZ 50).
FeNO and EBC pH values according to asthma
control
Exhaled NO and exhaled breath condensate (EBC) pH values
in the whole population and in the 4 subgroups are pre-
sented in Table 2. Patients with partly controlled asthma
had higher FeNO and lower EBC pH values compared to
those with well-controlled asthma. This was evident in the
whole study population and also in groups 1, 2 and 3.
Additionally, patients with uncontrolled asthma had higher
FeNO and EBC pH values compared to those with partly orTable 1 Patients’ demographics and parameters related to ast
All (n Z 274) Well controlled (n Z 99
Age (years) 50  17 51  18
Gender (F/M) 166/109 64/35
BMI (kg/m2) 27.9  4.9 28.5  4.7
Smokers (%) 83 (30.3%) 31 (31.3%)
FEV1 (% pred.) 85  19 94  17
ICS-treated (%) 194 (70.8%) 67 (67.7%)
ACQ 1.43 (0.71e2.71) 0.57 (0.29e0.86)
ACT 19 (16e23) 23 (22e24)
Normally distributed data are presented as mean  SD; skewed data
data as n (%). BMI: body-mass index; FEV1: forced expiratory volume
tionnaire (Juniper); ACT: asthma control test.well-controlled asthma in the groups of non-smokers
(groups 1 and 3). In group 2, FeNO and EBC pH values in
patients with uncontrolled asthma were statistically
significant different from those with well-controlled
asthma, but did not differ from those with partly controlled
disease. Finally, in group 4 (ICS-treated smokers) there
were no statistically significant differences between the
three groups in either FeNO or EBC pH.
Diagnostic performance of FeNO and EBC pH for the
identification of not well-controlled asthma
The diagnostic performance of FeNO, EBC pH and their
combination (i.e. the presence of either one of the two
biomarkers) for the identification of patients with not well-
controlled (i.e. partly controlled or uncontrolled) asthma is
presented in Table 3 and the corresponding ROC curves are
shown in Fig. 1. For the whole study population, the
performance characteristics for both FeNO and EBC pH, as
judged by the AUCs, were significant (>0.7) but modest
(<0.9). FeNO provided a PPV of 0.89 at a cut-point of
>24 ppb, whereas EBC pH provided a PPV of 0.81 for a cut-
point of 7.37. However, the diagnostic performance of
both biomarkers and their combination was inferior to
those of ACQ (AUC 0.880, 95% CI 0.835 to 0.916) or ACT
(0.918, 95% CI 0.879 to 0.948) (Fig. 1).
In group 1 the diagnostic performance of FeNO was
better compared to EBC pH or the combination of the two
biomarkers (AUC Z 0.899, PPV Z 0.90 at a cut-point of
>22 ppb). In Group 2, in contrast, the diagnostic perfor-
mance of EBC pH was superior to that of FeNO, yielding
a PPV of 0.85 at a cut-point of 7.21, as was the combi-
nation of the two biomarkers. In Group 3, the diagnostic
performance was comparable for both biomarkers and their
combination, with FeNO providing a PPV of 0.95 for values
>27 ppb. Finally, in Group 4, the diagnostic performance
was poor for both biomarkers. In this group the combination
of the two biomarkers improved their diagnostic
performance.
Evaluation of the diagnostic performance of FeNO
and EBC pH at different cut-points
In the evaluation of different cut-off points we observed
that FeNO values >30 ppb provide PPV >0.90 for thehma control.
) Partly controlled (n Z 115) Uncontrolled (n Z 60)
51  17 46  15
68/47 36/24
27.5  5.1 28.0  5.0
33 (28.7%) 19 (31.7%)
83  16 74  21
91 (79.1%) 36 (60.0%)
1.86 (1.14e2.71) 3.43 (2.57e4.00)
18 (17e19) 14 (11e17)
are presented as median (interquartile ranges); and categorical
in 1 s; ICS: inhaled corticosteroids; ACQ: asthma control ques-
Table 2 Exhaled NO and exhaled breath condensate (EBC) pH values in the whole population and in the 4 subgroups.
All (n Z 274) Well controlled
(n Z 99)
Partly controlled
(n Z 115)
Uncontrolled
(n Z 60)
All (n Z 274) FeNO 22 (16e41) 16 (13e20) 27 (19e44)* 59 (23e111)*,#
EBC pH 7.29 (7.14e7.43) 7.44 (7.34e7.57) 7.25 (7.12e7.36)* 7.14 (7.05e7.21)*,#
Group 1 (n Z 48) FeNO 30 (18e111) 16 (14e21) 40 (27e105)* 116 (63e145)*,#
EBC pH 7.25 (7.16e7.40) 7.43 (7.27e7.45) 7.25 (7.19e7.34)* 7.11 (7.08e7.22)*,#
Group 2 (n Z 32) FeNO 19 (14e22) 16 (12e19) 21 (15e38)* 22 (21e108)*
EBC pH 7.32 (7.14e7.47) 7.47 (7.40e7.58) 7.19 (7.12e7.33)* 7.15 (7.03e7.21)*
Group 3 (n Z 144) FeNO 23 (16e44) 16(12e20) 28 (20e44)* 61 (35e78)*,#
EBC pH 7.31 (7.15e7.45) 7.48 (7.34e7.59) 7.29 (7.12e7.36)* 7.15 (7.08e7.21)*,#
Group 4 (n Z 50) FeNO 19 (14e25) 17 (14e22) 19 (13e25) 23 (17e74)
EBC pH 7.24 (7.10e7.41) 7.38 (7.26e7.53) 7.21 (7.06e7.41) 7.11 (6.96e7.54)
Data are presented as median (interquartile ranges). FeNO values are expressed in ppb at a flow rate of 50 mL/s *p < 0.05 compared to
controlled asthma; #p < 0.05 compared to partly controlled asthma. Group 1: ICS-untreated e Non-Smokers; Group 2: ICS-untreated e
Smokers; Group 3: ICS-treated e Non-Smokers; Group 4: ICS-treated e Smokers.
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whole population and in the two groups of non-smokers
(Groups 1 and 3, Table 4 Online supplement). However, this
was at the cost of low NPV, suggesting that low FeNO values
are not useful for the identification of well-controlled
asthma.
Additionally, EBC pH values 7.20 provide PPV >0.80 for
the identification of not well-controlled asthma (Table 5
Online supplement). In contrast, the higher PPVs in the
groups of smokers (0.84 for Group 2 and 0.86 for Group 4)
may suggest a possible role for low EBC pH for the identi-
fication of not well-controlled asthma in asthmatic
smokers. Again, this was at the cost of low NPV, suggesting
that high values of EBC pH are not useful for the identifi-
cation of well-controlled asthma.
A scatterplot of FeNO and EBC pH levels of individual
patients according to their level of control is presented in
Fig. 2. The majority of well-controlled patients are classi-
fied in the lower right quartile of the graph (FeNO <30 andTable 3 Diagnostic performance characteristics of exhaled NO
well-controlled (partly or uncontrolled) asthma in the whole study
points based on maximum AUCs with ROC analyses, are given.
Cut-point Sensitivity Specifi
All (n Z 274) FeNO >24 ppb 0.61 0.87
pH 7.37 0.85 0.66
Combination 0.93 0.66
Group 1 (n Z 48) FeNO >22 ppb 0.87 0.81
pH 7.36 0.91 0.63
Combination 0.97 0.50
Group 2 (n Z 32) FeNO >19 ppb 0.56 0.75
pH 7.21 0.69 0.88
Combination 0.81 0.75
Group 3 (n Z 144) FeNO >27 ppb 0.64 0.94
pH 7.39 0.92 0.65
Combination 0.93 0.63
Group 4 (n Z 50) FeNO >23 ppb 0.45 0.87
pH 7.25 0.66 0.80
Combination 0.77 0.73
CI: confidence intervals, PPV: positive predictive value, NPV: negative
untreated e Non-Smokers; Group 2: ICS-untreated e Smokers; GroupEBC pH >7.20). Only 16 of 99 well-controlled patients
(16.2%) had either FeNO values of >30 and/or EBC pH
7.20. Additionally, 121 of the 137 patients (88.3%) that
presented with partly controlled or uncontrolled asthma
had FeNO >30 and/or EBC pH 7.20.
Diagnostic performance of FeNO and EBC pH for the
differentiation between uncontrolled and partly
controlled asthma
The diagnostic performance of both biomarkers (and their
combination) for the differentiation between uncontrolled
and partly controlled asthma was poor, and this was even
more prominent in smokers (data not shown).
Discussion
To our knowledge this is the first study to assess two
completely non-invasive exhaled biomarkers for the, EBC pH and their combination for the identification of not
population and in the 4 subgroups. Data for the optimum cut-
city PPV NPV AUC (95%CI) p-value
0.89 0.56 0.790 (0.737e0.837) <0.0001
0.81 0.71 0.791 (0.738e0.837) <0.0001
0.81 0.71 0.754 (0.699e0.804) <0.0001
0.90 0.76 0.899 (0.778e0.967) <0.0001
0.83 0.77 0.734 (0.587e0.851) 0.004
0.79 0.89 0.734 (0.587e0.851) <0.0001
0.69 0.63 0.680 (0.492e0.833) 0.059
0.85 0.74 0.795 (0.616e0.916) 0.0003
0.76 0.80 0.781 (0.600e0.907) 0.0007
0.95 0.60 0.844 (0.775e0.899) <0.0001
0.82 0.83 0.836 (0.765e0.892) <0.0001
0.82 0.85 0.785 (0.709e0.849) <0.0001
0.89 0.41 0.597 (0.449e0.733) 0.256
0.89 0.50 0.682 (0.535e0.806) 0.036
0.87 0.58 0.752 (0.610e0.863) 0.003
predictive value, AUC: area under the ROC curve. Group 1: ICS-
3: ICS-treated e Non-Smokers; Group 4: ICS-treated e Smokers.
Figure 1 Receiver operating characteristics (ROC) curves for
FeNO, EBC pH and their combination in the identification of not
well-controlled asthma in the whole study population. Squares
(-) indicate the optimal cut-off points for FeNO (>24 ppb),
EBC pH (7.37), their combination, ACQ (1.5) and ACT (20).
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population of asthmatics.We have shown that both FeNO and
EBC pH, two easily performed on-site exhaled biomarkers,
are related to the level of asthma control as defined in the
GINA guidelines.1 We have also observed that FeNO is helpful
for the identification of not well-controlled asthma, per-
forming better in non-smokers, whereas EBC pH was more
effective in the identification of not well-controlled asthma
in smokers. A complementary role for the two biomarkers in
the identification of not well-controlled asthmatics in theFigure 2 Scatterplot of the whole study population accord-
ing to the level of asthma control: well controlled ( ) vs. partly
controlled or uncontrolled ( ). The dashed lines represent the
optimal cut-points for FeNO (30 ppb) and EBC pH (7.20),
according to ROC analysis.group of smokers receiving ICSwas observed. The presence of
FeNO >30 and/or EBC pH 7.20 was indicative of partly or
uncontrolled asthma in 88.3% of the patients. However, the
performance of FeNO, EBC pH and their combination was
inferior to clinical judgment and ACQ or ACT in the whole
population.
Biomarkers of airway inflammation are under evaluation
for the guidance of asthma management. Studies have
shown that treatment strategies aiming at normalization of
induced sputum eosinophils may reduce exacerbations,9
especially eosinophilic ones,26 without the need for addi-
tional anti-inflammatory treatment.9,26 However, sputum
induction is time-consuming and requires a dedicated
laboratory. In contrast, FeNO is non-invasive, is measured
in a few minutes and is responsive to changes in inhaled
corticosteroid doses.11 However, studies using FeNO guid-
ance for asthma treatment have been controversial,27,28
and this may reflect differences in design and the fact
that cut-points used may reflect values from a normal
population instead of the population of interest.11
Our study adds to this field as it provides data on the
levels of FeNO that may be of clinical importance in the
assessment of asthma control in everyday clinical practice.
In a recent study Michils et al. showed that FeNO values
>45 ppb exclude a well-controlled asthma with an NPV of
0.89.13 In a similar manner, we have shown that FeNO
values >30 ppb are suggestive of not well-controlled
asthma with PPVs >0.80, with better performance in non-
smokers (PPVs >0.90). Differences in study design may
account for the lower cut-off point in our study, since in our
study we did not exclude smokers and asthma control was
prospectively evaluated by a chest physician, in contrast to
the study by Michils et al. where asthma control was eval-
uated by a post-hoc analysis of ACQ data. The performance
of both ACQ and ACT was superior to that of FeNO, EBC pH
and their combination in our study, yet it was inferior and
cannot substitute for the clinical evaluation by clinicians
with special interest in asthma.
The interpretation of FeNO has to take account of
several confounding factors, two of the most important
being smoking habit and the use of ICS. A recent study has
shown that sequential changes in FeNO are related to
asthma control even in smokers.14 Our present data clearly
show that this is not the case for the cross-sectional
assessment of single FeNO measurements in smoking asth-
matics. In contrast, we have shown that EBC pH may be of
greater importance in smokers, as evaluated by the corre-
sponding AUCs in Groups 2 and 4 of our study. Especially in
smokers not treated with ICS at the time of the interpre-
tation, EBC pH presents an acceptable performance
(AUC Z 0.795) with a PPV of 0.85 for values 7.21. More-
over, the bad performance of both single biomarkers in
Group 4 may be partly compensated by using the combi-
nation of the two, providing an AUC of 0.752.
EBC pH has never been previously evaluated in the
assessment of asthma control. The rationale for the use of
EBC pH lies in the fact that patients with acute asthma
present lower pH values that resolve with treatment.15 We
have previously shown that pH values in stable patients with
mild asthma do not differ from controls, whereas patients
with moderate asthma have lower pH values.16 Additionally,
patients on ICS have higher EBC pH values that do not differ
FeNO and EBC pH in asthma control 531from controls.16 In a recent study we have highlighted
a possible role for smoking in the regulation of endogenous
airways acidification in patients with allergic rhinitis.17 The
present data further support our previous observations and
suggest that patients with partly or uncontrolled asthma
present with lower EBC pH values compared to those with
well-controlled disease. An additional role of smoking was
evident in Group 2 patients (ICS-untreated smokers) but was
eliminated in Group 4 (ICS-treated smokers). However, even
in that group, EBCpH remainedabetter biomarker compared
toFeNO for the identification ofnotwell-controlledpatients.
This may be attributed both to the fact that smoking asth-
matics present lower FeNO values compared to non-
smokers29 and to a possible association of lower EBC pH with
neutrophilic airways inflammation, as we have previously
shown for patients with COPD or bronchiectasis.16 Smoking
has been shown to lead to an alteration of the inflammatory
pattern in favor of a more neutrophilic type of inflammation
in asthmatics.30 Finally, EBCpHhas been related to the levels
of oxidative stress in smokers with moderate to severe
asthma,18 further supporting a possible role of EBC pH in
confirming true loss of control in such patients, as suggested
by our data.
In the evaluation of different cut-points for the identi-
fication of not well-controlled asthma we have shown that
a single value of FeNO >30 ppb provides PPVs >0.90 in the
non-smoking asthmatics, however at the cost of low NPV.
This is in accordance with previous studies showing that
high FeNO values present high specificity and low sensitivity
for the diagnosis of asthma.22,31 Our results are similar, yet
in the present study we have chosen to evaluate cut-points
with high PPV (i.e. those that provide minimal risk to miss
a patient with not well-controlled asthma),32 since our
study population is representative of the patients evalu-
ated in asthma clinics. Interestingly, and despite the low
diagnostic performance of FeNO in Group 4, values >30 ppb
provided a PPV of 0.83, suggesting that high FeNO values
are indicative of poor asthma control even in this subgroup
of ICS-treated smoking patients.
The evaluation of different cut-off points for EBC pH
revealed that values 7.20 provide PPVs >0.80 in the whole
population and in all subgroups. The corresponding PPVs for
the groups of smokers (Groups 2 and 4) were 0.84 and 0.86,
suggesting that only a small fraction of patients with not
well-controlled asthma will have lower values. This is the
first study to our knowledge that evaluates cut-points of
EBC pH for the identification of asthma control. It has to be
pointed out that, in a similar manner to FeNO, this is at the
cost of low NPVs, suggesting that EBC pH is not useful for
the identification of well-controlled patients. However, in
clinical practice the major need is to identify not well-
controlled patients, since these are the patients where an
intervention is urgently needed. Inaccurate perception of
symptoms is often found in asthma patients8 and especially
in certain groups, including obese patients,6 persons with
psychosocial problems7 and adolescents.33 Interestingly,
adolescents with asthma are at higher risk for depression,
cigarette smoking and drug abuse34 that may lead to poorer
adherence to medication.35 Therefore, the need for
biomarkers that accurately identify patients with not well-
controlled asthma is imperative, especially in certain
subgroups of asthmatic patients, and FeNO and EBC pH mayprovide useful information in non-smokers and smokers,
respectively.
In conclusion, we have shown that FeNO and EBC pH
levels may be useful in the identification of patients with
not well-controlled asthma. The performance of FeNO was
better in non-smokers and in patients not receiving ICS,
whereas EBC pH performed better in smokers. A comple-
mentary role for the two biomarkers was demonstrated in
smokers treated with ICS. However, their performance was
inferior to clinical judgment and may be limited to selected
subgroups of asthmatic patients. Further longitudinal
studies for the prospective evaluation of the performance
of the two biomarkers to guide the management asthmatic
patients are clearly justified.
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